SW · RO.SW
Roche Holding AG
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Basel 4070
- Website
- roche.com
Price · as of 2025-12-31
$326.60
Market cap 297.07B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $373.22 | +14.27% |
| Intrinsic Value(DCF) | $177.05 | -45.79% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $109.89 | -66.35% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $110.83 | $155.18 | $36.70 | $0.00 | $0.00 |
| 2012 | $148.27 | $192.50 | $46.80 | $0.00 | $166.78 |
| 2013 | $177.89 | $218.78 | $90.24 | $0.00 | $192.67 |
| 2014 | $197.85 | $214.62 | $116.10 | $0.00 | $116.70 |
| 2015 | $178.78 | $198.23 | $96.05 | $0.00 | $94.64 |
| 2016 | $188.82 | $213.84 | $106.12 | $0.00 | $138.69 |
| 2017 | $170.09 | $216.13 | $103.57 | $0.00 | $140.37 |
| 2018 | $223.84 | $264.73 | $172.67 | $0.00 | $179.94 |
| 2019 | $229.81 | $278.53 | $231.15 | $0.00 | $236.79 |
| 2020 | $270.66 | $289.15 | $67.99 | $0.00 | $0.00 |
| 2021 | $348.81 | $293.89 | $64.47 | $0.00 | $252.38 |
| 2022 | $254.64 | $287.96 | $54.92 | $0.00 | $197.52 |
| 2023 | $226.40 | $266.73 | $34.57 | $0.00 | $4.13 |
| 2024 | $314.02 | $308.41 | $37.08 | $0.00 | $116.22 |
| 2025 | $373.20 | $373.22 | $48.98 | $0.00 | $109.89 |
AI valuation
Our deep-learning model estimates Roche Holding AG's (RO.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $373.22
- Current price
- $326.60
- AI upside
- +14.27%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$177.05
-45.79% upside
Graham-Dodd
—
— upside
Graham Formula
$109.89
-66.35% upside
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
- CEO
- Thomas Schinecker
- Employees
- 103.25K
- Beta
- 0.20
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($177.05 ÷ $326.60) − 1 = -45.79% (DCF, example).